亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

POS0230 DISAGREEMENT BETWEEN PATIENT AND PHYSICIAN GLOBAL ASSESSMENT OVER TIME IN PSORIATIC ARTHRITIS: INSIGHT INTO TREATMENT PRIORITIES

医学 内科学 逻辑回归 银屑病性关节炎 强直性脊柱炎 类风湿性关节炎
作者
P. Rahman,Laura C. Coates,Peter Nash,Atul Deodhar,F. Nantel,Emmanouil Rampakakis,Louis Bessette,M. Marrache,F. Lavie,M. Shawi,William Tillett
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:82: 345-346
标识
DOI:10.1136/annrheumdis-2023-eular.464
摘要

Background

The PsA core domain set developed by the Outcome Measures in Rheumatology working group includes musculoskeletal disease, fatigue, physical function, and structural damage, of which arthritis activity, pain, and fatigue were identified as essential by both patients (Pts) and physicians (Phs).[1-2] Assessing agreement between Pt and Ph global assessments (GA) may provide valuable insight into differential importance of specific PsA manifestations to Pts vs Phs. Although previous studies have assessed Pt/Ph disagreement, they have not evaluated potential variation over time.[3]

Objectives

To assess agreement of PtGA and PhGA through week (W) 24 and identify factors driving disagreement between PtGA and PhGA using pooled data (N=1120) from the phase 3 DISCOVER (D)-1 & -2 studies of the fully human IL-23p19 subunit inhibitor (i), guselkumab (GUS).

Methods

Pts with active PsA despite standard therapies (D1: ≥3 swollen/tender joint counts [SJC/TJC], CRP ≥0.3 mg/dL, ~30% with prior TNFi; D2: ≥5 SJC/TJC, CRP ≥0.6 mg/dL, biologic-naïve) were randomized 1:1:1 to GUS 100 mg every 4 weeks (Q4W); GUS 100 mg at W0, W4, Q8W; or placebo. Pt/Ph agreement was defined as a difference of -15<PhGA-PtGA<15. Determinants of PhGA exceeding PtGA by ≥15 (PhGA>PtGA) and PtGA exceeding PhGA by ≥15 (PtGA>PhGA) among pts with PtGA/PhGA disagreement were assessed with the same logistic regression model considering pt demographics, disease characteristics, and pt-reported outcomes (PROs). The effect of GUS on disease parameters identified as determinants of PtGA vs. PhGA disagreement was assessed with repeated measures mixed models adjusting for treatment group, baseline (BL) levels, prior TNFi use, and BL DMARD use.

Results

At BL, mean (SD) SJC=11.5 (7.4), TJC=20.6 (13.3), FACIT-Fatigue score=29.9 (10.0), PtGA=66.9 (19.9), and PhGA=64.8 (15.9) were consistent with moderate to high disease activity. Agreement between PtGA and PhGA was seen in most instances (61.2%); 23.2% of cases were characterized by PtGA>PhGA and 15.7% by PhGA>PtGA. The proportion of pts with PtGA>PhGA increased to 39.1% at W24, while that with PhGA>PtGA decreased to 11.2%. The main determinant of PtGA>PhGA was higher Pt Pain (all time points); additional factors included worse physical health-related quality of life at BL and worse fatigue at W24 (Table 1). Conversely, Phs emphasized objective disease measures, namely higher SJC (all time points) and TJC (W8 to W24), and elevated CRP (BL to W16). GUS treatment was associated with prompt and sustained significant improvements in all identified determinants, including those driving PtGA>PhGA (Figure 1).

Conclusion

PtGA and PhGA were aligned in most encounters. PtGA>PhGA disagreement was driven by pain, fatigue, and physical health being weighed more by Pts than Phs. These findings have important implications in shared decision making and highlight the need to prioritize treatments addressing the full spectrum of PsA symptoms, including PROs.

References

[1]Leung YY, et al. J Rheum. 2020 (Suppl);96:46 [2]Mease PJ, et al. Ann Rheum Dis. 2022;81:879 [3]Desthieux C, et al. Arthritis Care Res. 2017;69:1606

Acknowledgements:

NIL.

Disclosure of Interests

Proton Rahman Consultant of: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, and UCB, Grant/research support from: Janssen and Novartis, Laura Coates Speakers bureau: AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Medac, Novartis, Pfizer and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Peter Nash Grant/research support from: AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Pfizer, Novartis, Roche, Sandoz, and Sun Pharmaceutical Industries, Atul Deodhar Speakers bureau: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Aurinia, Bristol Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, MoonLake, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, and UCB, Francois Nantel Shareholder of: Johnson & Johnson, Consultant of: Janssen, Emmanouil Rampakakis Consultant of: Janssen, Employee of: JSS Medical Research, Louis Bessette Speakers bureau: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Fresenius Kabi, Janssen, MSD, Novartis, Pfizer, Sandoz, Sanofi, Teva, and UCB, Consultant of: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Fresenius Kabi, Gilead, Janssen, MSD, Novartis, Pfizer, Sandoz, Sanofi, Teva, and UCB, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Sanofi, and UCBA, Marilise Marrache Shareholder of: Johnson & Johnson, Employee of: Janssen Inc., Toronto, Canada, Frederic Lavie Shareholder of: Johnson & Johnson, Employee of: Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, May Shawi Shareholder of: Johnson & Johnson, Employee of: Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, William Tillett Speakers bureau: AbbVie, Amgen, Eli Lilly, Janssen, MSD, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Eli Lilly, Janssen, MSD, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen, Eli Lilly, Janssen, and UCB.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
13秒前
amiee发布了新的文献求助10
17秒前
43秒前
清爽友蕊发布了新的文献求助10
47秒前
彭于晏的应助被yhr采纳,获得10
54秒前
yipmyonphu的应助被张阳采纳,获得10
55秒前
Maestro_S的应助被萧雨墨采纳,获得10
57秒前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
蔡文姬发布了新的文献求助10
1分钟前
呼啦呼啦完成签到 ,获得积分10
1分钟前
1分钟前
YWD完成签到,获得积分10
2分钟前
2分钟前
矢思然完成签到,获得积分10
2分钟前
追寻的怜容发布了新的文献求助200
2分钟前
王子努力搞科研完成签到 ,获得积分10
2分钟前
2分钟前
yhr发布了新的文献求助10
2分钟前
孤独难胜完成签到,获得积分10
2分钟前
3分钟前
3分钟前
3分钟前
Negiiii发布了新的文献求助10
3分钟前
乐观的书竹完成签到,获得积分10
3分钟前
研友_VZG7GZ的应助被渟柠采纳,获得30
4分钟前
4分钟前
科研通AI6.4的应助被amiee采纳,获得10
4分钟前
NA01UM10发布了新的文献求助10
4分钟前
铁瓜李完成签到 ,获得积分10
4分钟前
感动初蓝完成签到 ,获得积分10
4分钟前
4分钟前
怕孤单的雪瑶完成签到,获得积分10
4分钟前
4分钟前
渟柠发布了新的文献求助30
4分钟前
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190136
求助须知:如何正确求助?哪些是违规求助? 9577239
关于积分的说明 21852194
捐赠科研通 7788466
什么是DOI,文献DOI怎么找? 3436259
关于科研通互助平台的介绍 2560043
邀请新用户注册赠送积分活动 2482880